What compounds target CHEK1?

BiohacksAI has identified 34 compounds that interact with CHEK1 (checkpoint kinase 1). Top compounds include: tozasertib, bosutinib, midostaurin, brigatinib, silmitasertib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is CHEK1 (checkpoint kinase 1)?

CHEK1 is checkpoint kinase 1. It is a molecular target for 34 compounds documented in PubMed bioassay data. NCBI Gene ID: 1111.

CHEK1

MOLECULAR TARGET

checkpoint kinase 1

NCBI Gene: 111134 compounds

CHEK1 (checkpoint kinase 1) is targeted by 34 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CHEK1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	tozasertib	4.33	75
2	bosutinib	4.08	58
3	midostaurin	3.85	46
4	brigatinib	3.81	44
5	silmitasertib	3.78	43
6	neratinib	3.66	38
7	nintedanib	3.61	36
8	pelitinib	3.50	32
9	tae 684	3.43	30
10	fedratinib	3.40	29
11	dovitinib	3.09	21
12	at 9283	3.09	21
13	lestaurtinib	3.04	20
14	pf 03758309	3.00	19
15	hymenialdisine	3.00	19
16	ruboxistaurin	2.94	18
17	r 406	2.83	16
18	k 252a	2.83	16
19	pd 0166285	2.83	16
20	kw 2449	2.64	13
21	isogranulatimide	2.56	12
22	debromohymenialdisine	2.56	12
23	doxantrazole	2.40	10
24	azd 7762	2.30	9
25	granulatimide	2.30	9
26	su 014813	2.20	8
27	prexasertib	2.08	7
28	cerdulatinib	1.95	6
29	sra 737	1.95	6
30	pf 03814735	1.79	5
31	ucn 01	1.79	5
32	rabusertib	1.79	5
33	kenpaullone	0.69	1
34	sp600125	0.69	1

About CHEK1 as a Drug Target

CHEK1 (checkpoint kinase 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 34 compounds with documented CHEK1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CHEK1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.